Literature DB >> 27121783

Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers.

Teddy Kosoglou1, Larisa Reyderman1, Jack Tseng1, Bharath Kumar1, Fengjuan Xuan1, James Schiller1, Alan G Meehan1, Kenneth Kim2, David L Cutler1.   

Abstract

This randomized, open-label, parallel group study examined the effects of food, antacid, and age on the pharmacokinetics of vorapaxar. In total, 101 subjects were enrolled including 83 young adults (18-45 years) and 18 elderly subjects (>65 years). Subjects received single-dose vorapaxar 40 mg after a 10-hour fast (young and elderly) or with extra-strength antacid, food, or 1 or 2 hours after food (young only). Vorapaxar 40 mg was rapidly absorbed after a fast (median Tmax : 1 hour). Administration with food or 1 or 2 hours post-meal modestly increased vorapaxar mean area under the curve (AUC) and Cmax and prolonged median Tmax by 1 hour. Concomitant food modestly increased vorapaxar AUC from time zero to infinity [AUC(I)] and Cmax 43% and 31%, respectively. Antacid modestly decreased vorapaxar AUC(I) by 15% and Cmax by 38%, and increased median Tmax by 1 hour. Vorapaxar AUC(I) and Cmax were 41% and 29% higher, respectively, in elderly versus young subjects. Concomitant food and older age were associated with modest increases, and antacid was associated with a small decrease in vorapaxar exposure, which are not expected to affect the drug's safety or efficacy.
© The Author(s) 2013.

Entities:  

Keywords:  SCH 530348; Vorapaxar; age; antacid; food; interaction; pharmacokinetics

Year:  2013        PMID: 27121783     DOI: 10.1002/cpdd.30

Source DB:  PubMed          Journal:  Clin Pharmacol Drug Dev        ISSN: 2160-763X


  4 in total

1.  Exploring the Relationship of Drug BCS Classification, Food Effect, and Gastric pH-Dependent Drug Interactions.

Authors:  Katie Owens; Sophie Argon; Jingjing Yu; Xinning Yang; Fang Wu; Sue-Chih Lee; Wei-Jhe Sun; Anuradha Ramamoorthy; Lei Zhang; Isabelle Ragueneau-Majlessi
Journal:  AAPS J       Date:  2021-12-27       Impact factor: 4.009

Review 2.  Vorapaxar: first global approval.

Authors:  Raewyn M Poole; Shelley Elkinson
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 3.  Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.

Authors:  Rebecca J Gryka; Leo F Buckley; Sarah M Anderson
Journal:  Drugs R D       Date:  2017-03

Review 4.  Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.

Authors:  Judy Wm Cheng
Journal:  Vasc Health Risk Manag       Date:  2016-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.